Scandinavian ChemoTech AB (publ) (CMOTEC-B.ST)
SEK 1.48
(0.68%)
SEK 1.48
(0.68%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 2.82 Million SEK | 496.62% |
| 2022 | 473 Thousand SEK | 865.31% |
| 2021 | 49 Thousand SEK | -62.6% |
| 2020 | 131 Thousand SEK | -76.44% |
| 2019 | 556 Thousand SEK | -0.71% |
| 2018 | 560 Thousand SEK | 1955.57% |
| 2017 | 27.24 Thousand SEK | -98.69% |
| 2016 | 2.08 Million SEK | 14901.89% |
| 2015 | 13.89 Thousand SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| 2013 | - SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 1.68 Million SEK | 24.98% |
| 2024 Q1 | 1.34 Million SEK | 165.29% |
| 2023 Q2 | 1.18 Million SEK | 2087.04% |
| 2023 Q4 | 507 Thousand SEK | -53.06% |
| 2023 FY | 2.82 Million SEK | 496.62% |
| 2023 Q1 | 54 Thousand SEK | -76.21% |
| 2023 Q3 | 1.08 Million SEK | -8.55% |
| 2022 Q2 | 72 Thousand SEK | 30.91% |
| 2022 FY | 473 Thousand SEK | 865.31% |
| 2022 Q4 | 227 Thousand SEK | 90.76% |
| 2022 Q3 | 119 Thousand SEK | 65.28% |
| 2022 Q1 | 55 Thousand SEK | 450.0% |
| 2021 FY | 49 Thousand SEK | -62.6% |
| 2021 Q1 | 25 Thousand SEK | -85.12% |
| 2021 Q2 | 5000.00 SEK | -80.0% |
| 2021 Q3 | 9000.00 SEK | 80.0% |
| 2021 Q4 | 10 Thousand SEK | 11.11% |
| 2020 Q2 | 376 Thousand SEK | 317.78% |
| 2020 FY | 131 Thousand SEK | -76.44% |
| 2020 Q3 | 41 Thousand SEK | -89.1% |
| 2020 Q1 | 90 Thousand SEK | 25.0% |
| 2020 Q4 | 168 Thousand SEK | 309.76% |
| 2019 FY | 556 Thousand SEK | -0.71% |
| 2019 Q2 | 454 Thousand SEK | 2170.0% |
| 2019 Q4 | 72 Thousand SEK | 700.0% |
| 2019 Q1 | 20 Thousand SEK | -83.99% |
| 2019 Q3 | 9000.00 SEK | -98.02% |
| 2018 Q3 | 124.99 Thousand SEK | 19.95% |
| 2018 FY | 560 Thousand SEK | 1955.57% |
| 2018 Q4 | 124.93 Thousand SEK | -0.05% |
| 2018 Q2 | 104.21 Thousand SEK | -49.38% |
| 2018 Q1 | 205.86 Thousand SEK | 0.0% |
| 2017 Q1 | 37.68 Thousand SEK | -95.58% |
| 2017 FY | 27.24 Thousand SEK | -98.69% |
| 2017 Q3 | 2.00 SEK | -100.0% |
| 2017 Q2 | 490.04 Thousand SEK | 1200.23% |
| 2016 Q1 | 13.89 Thousand SEK | -92.58% |
| 2016 FY | 2.08 Million SEK | 14901.89% |
| 2016 Q4 | 851.91 Thousand SEK | 0.0% |
| 2016 Q2 | 500.54 Thousand SEK | 3502.61% |
| 2016 Q3 | - SEK | -100.0% |
| 2015 Q4 | 187.2 Thousand SEK | 100.0% |
| 2015 Q3 | 93.6 Thousand SEK | 0.0% |
| 2015 FY | 13.89 Thousand SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |
| 2013 FY | - SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 58.1 Million SEK | 95.143% |
| Ziccum AB (publ) | 3.74 Million SEK | 24.686% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 615.99 Million SEK | 99.542% |
| Sprint Bioscience AB (publ) | 50.48 Million SEK | 94.41% |
| Mendus AB (publ) | 28.48 Million SEK | 90.094% |
| Genovis AB (publ.) | 158.23 Million SEK | 98.217% |
| Intervacc AB (publ) | 8.01 Million SEK | 64.791% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 4.37 Million SEK | 35.482% |
| Active Biotech AB (publ) | - SEK | -Infinity% |
| Magle Chemoswed Holding AB (publ) | 170.44 Million SEK | 98.344% |
| Bio-Works Technologies AB (publ) | 43.89 Million SEK | 93.571% |
| Aptahem AB (publ) | 2.63 Million SEK | -7.274% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | 1.03 Million SEK | -172.657% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -3564.935% |
| Fluicell AB (publ) | 3.33 Million SEK | 15.458% |
| Saniona AB (publ) | 16.84 Million SEK | 83.242% |
| Lipigon Pharmaceuticals AB (publ) | 16.4 Million SEK | 82.8% |
| Biovica International AB (publ) | 7.29 Million SEK | 61.289% |
| Spago Nanomedical AB (publ) | 1.2 Million SEK | -134.58% |
| AcouSort AB (publ) | 10.55 Million SEK | 73.254% |
| Xintela AB (publ) | 78 Thousand SEK | -3517.949% |
| Abliva AB (publ) | 137 Thousand SEK | -1959.854% |
| Egetis Therapeutics AB (publ) | 57.6 Million SEK | 95.101% |
| Karolinska Development AB (publ) | 2.01 Million SEK | -40.119% |
| OncoZenge AB (publ) | 3000.00 SEK | -93966.667% |
| Amniotics AB (publ) | - SEK | -Infinity% |
| 2cureX AB (publ) | 155 Thousand SEK | -1720.645% |
| CombiGene AB (publ) | 5.54 Million SEK | 49.099% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| Calliditas Therapeutics AB (publ) | 1.2 Billion SEK | 99.766% |
| Camurus AB (publ) | 1.71 Billion SEK | 99.836% |
| Corline Biomedical AB | 25.03 Million SEK | 88.726% |
| IRLAB Therapeutics AB (publ) | 5.67 Million SEK | 50.299% |
| Isofol Medical AB (publ) | 721 Thousand SEK | -291.401% |
| I-Tech AB | 120.86 Million SEK | 97.665% |
| Hansa Biopharma AB (publ) | 134.09 Million SEK | 97.896% |
| Cyxone AB (publ) | 5.14 Million SEK | 45.183% |
| ExpreS2ion Biotech Holding AB (publ) | 7.05 Million SEK | 59.972% |
| Biosergen AB | - SEK | -Infinity% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | 10.66 Million SEK | 73.539% |
| Xspray Pharma AB (publ) | - SEK | -Infinity% |
| Elicera Therapeutics AB (publ) | 11.23 Million SEK | 74.871% |
| Nanologica AB (publ) | 1.44 Million SEK | -95.565% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 53 Thousand SEK | -5224.528% |
| BioInvent International AB (publ) | 71.46 Million SEK | 96.051% |
| Alzinova AB (publ) | 270 Thousand SEK | -945.185% |
| Oncopeptides AB (publ) | 35.22 Million SEK | 91.988% |
| Pila Pharma AB (publ) | 1.46 Million SEK | -92.889% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Simris Alg AB (publ) | 4.35 Million SEK | 35.186% |
| Diamyd Medical AB (publ) | 130 Thousand SEK | -2070.769% |
| Xbrane Biopharma AB (publ) | 238.72 Million SEK | 98.818% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 23 Thousand SEK | -12169.565% |